Background
Care provided in the emergency department (ED) can cost up to 5 times
as much as care received for comparable diagnoses in alternative settings.
Small groups of patients, many of whom suffer from an opioid use disorder,
often account for a large proportion of total ED visits. We recently
conducted, and demonstrated the effectiveness of, the first randomized
controlled trial of a citywide ED care-coordination program intending to
reduce prescription-opioid-related ED visits. All EDs in the metropolitan
study area were connected to a web-based information exchange system.
Objective
The objective of this paper was to perform an economic evaluation of
the 12-month trial from a third-party-payer perspective.
Methods
We modeled the person period monthly for the 12-month observation
period, and estimated total treatment costs and return on investment (ROI)
with regard to cost offsets, over time, for all visits where the patient was
admitted to, and discharged from the ED.
Results
By the end of month 4 the mean cumulative cost differential was
significantly lower for intervention relative to TAU participants
(−$1,370; p=0.03); this figure climbed to
−$3,200 (p=0.02) by the end of month 12. The ROI
trended upward throughout the observation period, but failed to reach
statistical significance by the end of month 12 (ROI=3.39,
p=0.07).
Conclusion
The intervention produced significant cost offsets by the end of
month 4, which continued to accumulate throughout the trial; however, ROI
was not significant. Since the per-patient administrative costs of the
program are incurred at the time of enrollment, our results highlight the
importance of future studies that are able to follow participants for a
period beyond 12 months in order to more accurately estimate the
program’s ROI.